Market Price

61.70 

-0.40 -0.6%

as of May 21 '19

52 Week Range:

41.10 84.91


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Sysmex Corporation, together with its subsidiaries, engages in the development, manufacture, sale, and export/import of diagnostic instruments, reagents, and related software for the use in hematology, urinalysis, immunochemistry, clinical chemistry, and hemostasis. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; systems for high-volume testing in labs; and hematology analyzers for animals. The company also provides urine formed sediment analysis systems; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for to test for liver fibrosis progression and atopic dermatitis; and support services for hemostasis products. In addition, it offers systems for the detection of cancer lymph node metastasis; cytogenic testing services; and lab assay services. It serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. The company operates in the Americas, Europe, the Middle East, Africa, the Asia Pacific, China, and Japan. Sysmex Corporation has a collaboration with MolecularMD Corporation to develop and commercialize companion diagnostics; and a strategic collaboration with Biolidics Limited for the development of laboratory assays in the field of circulating tumor cells. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19
Equity (BVPS) 6.16
6.95
8.14
8.62
growth rate 12.8% 17.1% 5.9%
Earnings BIT 32,872.00
44,412.00
56,963.00
51,111.00
60,012.00
61,283.00
growth rate 35.1% 28.3% -10.3% 17.4% 2.1%
Avg.PE 30.41
30.28
41.03
33.58
growth rate -0.4% 35.5% -18.2%
ROA 7.04
8.16
9.10
8.82
8.99
10.72
11.61
14.05
14.78
12.99
growth rate 15.9% 11.5% -3.1% 1.9% 19.2% 8.3% 21.0% 5.2% -12.1%
ROE 10.10
11.71
12.60
12.22
12.79
15.50
16.87
20.26
20.35
17.36
growth rate 15.9% 7.6% -3.0% 4.7% 21.2% 8.8% 20.1% 0.4% -14.7%
ROIC 9.70
11.01
12.34
12.07
12.71
15.34
16.71
20.11
20.29
17.32
growth rate 13.5% 12.1% -2.2% 5.3% 20.7% 8.9% 20.4% 0.9% -14.6%
Cur. Ratio 2.02
2.40
2.58
2.60
2.52
2.33
2.37
2.62
2.77
2.61
growth rate 18.8% 7.5% 0.8% -3.1% -7.5% 1.7% 10.6% 5.7% -5.8%
Quick Ratio 1.26
1.55
1.71
1.75
1.74
1.61
1.67
1.83
2.03
1.90
growth rate 23.0% 10.3% 2.3% -0.6% -7.5% 3.7% 9.6% 10.9% -6.4%
Leverage 1.48
1.39
1.38
1.39
1.45
1.44
1.46
1.42
1.34
1.34
growth rate -6.1% -0.7% 0.7% 4.3% -0.7% 1.4% -2.7% -5.6% 0.0%
Balance Sheet Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19
Acct.Receivable 49,266.00
57,877.00
63,452.00
66,556.00
76,657.00
84,659.00
growth rate 17.5% 9.6% 4.9% 15.2% 10.4%
Acct.Payable 13,263.00
15,965.00
19,873.00
24,376.00
28,579.00
29,778.00
growth rate 20.4% 24.5% 22.7% 17.2% 4.2%
Cur.Assets 125,823.00
154,148.00
172,665.00
166,318.00
184,952.00
195,423.00
growth rate 22.5% 12.0% -3.7% 11.2% 5.7%
Total Assets 210,758.00
247,983.00
267,638.00
279,817.00
321,979.00
346,775.00
growth rate 17.7% 7.9% 4.6% 15.1% 7.7%
Cash 36,698.00
50,272.00
56,544.00
57,944.00
61,444.00
51,062.00
growth rate 37.0% 12.5% 2.5% 6.0% -16.9%
Inventory 27,318.00
29,887.00
35,621.00
36,998.00
40,975.00
40,231.00
growth rate 9.4% 19.2% 3.9% 10.8% -1.8%
Cur.Liabilities 54,010.00
65,170.00
65,895.00
59,952.00
70,796.00
71,247.00
growth rate 20.7% 1.1% -9.0% 18.1% 0.6%
Liabilities 64,509.00
78,433.00
79,545.00
69,566.00
80,537.00
81,594.00
growth rate 21.6% 1.4% -12.6% 15.8% 1.3%
LT Debt 105.00
growth rate
Equity 146,249.00
169,550.00
188,093.00
209,406.00
240,749.00
264,448.00
growth rate 15.9% 10.9% 11.3% 15.0% 9.8%
Common Shares 205.00
102.00
206.00
206.00
207.00
207.00
208.00
209.00
209.00
209.00
12,654.00
growth rate -50.2% 102.0% 0.0% 0.5% 0.0% 0.5% 0.5% 0.0% 0.0% 5,954.6%
Cash Flow Statement Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19
Capital Expenditures 13,282.00
13,033.00
13,685.00
11,682.00
16,573.00
18,726.00
growth rate -1.9% 5.0% -14.6% 41.9% 13.0%
Cash Dividends 4,544.00
6,734.00
9,549.00
11,646.00
12,493.00
14,600.00
growth rate 48.2% 41.8% 22.0% 7.3% 16.9%
Cash From OA 36,563.00
38,640.00
39,567.00
32,832.00
52,240.00
44,743.00
growth rate 5.7% 2.4% -17.0% 59.1% -14.4%
FCF per Share 0.77
0.75
0.58
1.03
growth rate -2.6% -22.7% 77.6%
Sale Purchase of Stock 877.00
396.00
849.00
928.00
1,036.00
growth rate -54.9% 114.4% 9.3% 11.6%
FCF 2,219.00
14,805.00
10,345.00
8,619.00
13,995.00
19,469.00
22,152.00
19,715.00
13,726.00
26,545.00
26,017.00
growth rate 567.2% -30.1% -16.7% 62.4% 39.1% 13.8% -11.0% -30.4% 93.4% -2.0%
Income Statement Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19
Sales 184,538.00
221,376.00
253,157.00
249,899.00
281,935.00
293,506.00
growth rate 20.0% 14.4% -1.3% 12.8% 4.1%
Op.Income 32,872.00
44,412.00
56,963.00
51,111.00
60,012.00
61,283.00
growth rate 35.1% 28.3% -10.3% 17.4% 2.1%
IBT 33,450.00
45,727.00
54,659.00
48,947.00
58,117.00
57,955.00
growth rate 36.7% 19.5% -10.5% 18.7% -0.3%
Net Income 20,573.00
26,638.00
36,233.00
40,636.00
39,222.00
41,224.00
growth rate 29.5% 36.0% 12.2% -3.5% 5.1%
EPS 39.12
95.25
55.48
29.16
68.53
99.16
128.02
188.30
194.74
187.84
growth rate 143.5% -41.8% -47.4% 135.0% 44.7% 29.1% 47.1% 3.4% -3.5%
Gross Profit 115,724.00
126,018.00
151,094.00
141,777.00
158,949.00
161,607.00
growth rate 8.9% 19.9% -6.2% 12.1% 1.7%
R&D 13,260.00
14,692.00
17,775.00
15,554.00
16,754.00
19,578.00
growth rate 10.8% 21.0% -12.5% 7.7% 16.9%

Quarterly Statements

Item Name Mar '18 Jun '18 Sep '18 Dec '18 Mar '19
Earnings BIT 15,428.00
13,832.00
14,672.00
14,067.00
18,712.00
growth rate -10.3% 6.1% -4.1% 33.0%
Balance Sheet Mar '18 Jun '18 Sep '18 Dec '18 Mar '19
Acct.Receivable 76,657.00
69,482.00
70,598.00
70,184.00
84,659.00
growth rate -9.4% 1.6% -0.6% 20.6%
Acct.Payable 28,579.00
23,167.00
24,560.00
25,565.00
29,778.00
growth rate -18.9% 6.0% 4.1% 16.5%
Cur.Assets 184,952.00
170,851.00
181,318.00
180,057.00
195,423.00
growth rate -7.6% 6.1% -0.7% 8.5%
Total Assets 321,979.00
308,257.00
325,476.00
323,444.00
346,775.00
growth rate -4.3% 5.6% -0.6% 7.2%
Cash 61,444.00
51,144.00
50,844.00
45,889.00
51,062.00
growth rate -16.8% -0.6% -9.8% 11.3%
Inventory 40,975.00
42,736.00
43,388.00
44,362.00
40,231.00
growth rate 4.3% 1.5% 2.2% -9.3%
Cur.Liabilities 70,796.00
56,899.00
61,381.00
61,776.00
71,247.00
growth rate -19.6% 7.9% 0.6% 15.3%
Liabilities 80,537.00
66,435.00
70,938.00
71,014.00
81,594.00
growth rate -17.5% 6.8% 0.1% 14.9%
Equity 240,749.00
241,178.00
253,929.00
251,730.00
264,448.00
growth rate 0.2% 5.3% -0.9% 5.1%
Common Shares 12,276.00
12,414.00
12,492.00
12,570.00
12,654.00
growth rate 1.1% 0.6% 0.6% 0.7%
Cash Flow Statement Mar '18 Jun '18 Sep '18 Dec '18 Mar '19
Capital Expenditures 7,986.00
2,819.00
6,606.00
2,861.00
6,440.00
growth rate -64.7% 134.3% -56.7% 125.1%
Cash Dividends 7,506.00
7,506.00
7,094.00
7,094.00
growth rate 0.0% -5.5% 0.0%
Cash From OA 18,014.00
3,296.00
16,130.00
9,666.00
15,651.00
growth rate -81.7% 389.4% -40.1% 61.9%
Sale Purchase of Stock 1,036.00
growth rate
FCF 10,028.00
477.00
9,524.00
6,805.00
9,211.00
growth rate -95.2% 1,896.7% -28.6% 35.4%
Income Statement Mar '18 Jun '18 Sep '18 Dec '18 Mar '19
Sales 79,384.00
65,961.00
70,233.00
72,177.00
85,134.00
growth rate -16.9% 6.5% 2.8% 18.0%
Op.Income 15,428.00
13,832.00
14,672.00
14,067.00
18,712.00
growth rate -10.3% 6.1% -4.1% 33.0%
IBT 12,987.00
12,765.00
13,645.00
13,520.00
18,024.00
growth rate -1.7% 6.9% -0.9% 33.3%
Net Income 8,667.00
9,424.00
10,049.00
9,433.00
12,317.00
growth rate 8.7% 6.6% -6.1% 30.6%
Gross Profit 43,771.00
37,639.00
38,893.00
39,275.00
45,801.00
growth rate -14.0% 3.3% 1.0% 16.6%
R&D 4,833.00
4,207.00
4,556.00
4,566.00
6,248.00
growth rate -13.0% 8.3% 0.2% 36.8%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

B (68.10)

YOY Growth Grade:

C (51.97)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 35.82 35.93
EPS / Growth 1.72

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 11.7%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 11.7% 11.7% 11.7%
Future PE 0.01 19.76 19.76
Future EPS 5.20 5.20 5.20
Value Price
MOS %
0.01
-100.0%
25.40
-58.8%
25.40
-58.8%
MOS Price 0.01 12.70 12.70
IRT 14.09 14.09 14.09

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.